Orchard Therapeutics has raised $34 million in new capital from the second closing of a securities purchase agreement, extending its cash runway through to mid-2025. The funding will support the advancement of its hematopoietic stem cell (HSC) gene therapy portfolio and preparations for the US launch of OTL-200 for MLD, pending FDA approval. The company expects that this funding will provide important capital to support preparations for its anticipated first US launch and advance its next-in-line neurometabolic programs derived from its HSC gene therapy platform. The completion of the biologics license application submission for OTL-200 is on track for mid-2023 with potential US approval in H1 2024.
Orchard Therapeutics is a global leader in discovering, developing and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. The company acquired GSK’s rare disease gene therapy portfolio in 2018, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy.